Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 18/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11497469 | 0.81 | CASR (0.71) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5527612 | 0.80 | CASR (0.59) | CASR | |
| Etolorex SCHEMBL164620 | 0.79 | SLC6A4 (0.48) | CASRADRB2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL21776166 | 0.79 | CASR (0.52) | CASR | |
| SCHEMBL355745 | 0.78 | CASR (0.51) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL14383134 | 0.78 | CASR (0.62) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5511560 | 0.77 | CASR (0.67) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5519885 | 0.77 | CASR (0.56) | CASRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5511543 | 0.77 | CASR (0.61) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL14004086 | 0.77 | LMNA (0.59) | CASRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| EP-4577550-A1 | NOVEL NLRP3 INFLAMMASOME INHIBITORS | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250206742-A1 | NLRP3 INFLAMMASOME INHIBITORS | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4565326-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119677725-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-113784957-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| EP-2954891-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA | ALMIRALL SA (ES) | 2022-05-04 | — | — | EP | disclosed |
| EP-2954889-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALMIRALL SA (ES) | 2022-05-04 | — | — | EP | disclosed |
| EP-3969441-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206742-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CASR 455/4885ADRB2 1062/4885ADRB3 483/4885 |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CASR 249/4885ADRB2 522/4885ADRB3 421/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | CASR 349/4885ADRB2 528/4885ADRB3 205/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CASR 249/4885ADRB2 522/4885ADRB3 421/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | CASR 1894/4885ADRB2 1/4885ADRB3 6/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CASR 349/4885ADRB2 528/4885ADRB3 205/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CASR 249/4885ADRB2 522/4885ADRB3 421/4885 |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | CASR 337/4885ADRB2 563/4885ADRB3 208/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CASR 349/4885ADRB2 528/4885ADRB3 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.